Last reviewed · How we verify
NCT06813157: MSC、ITP
Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
NA trial testing MSC in ITP - Immune Thrombocytopenia in 40 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Guangzhou Bio-gene Technology Co., Ltd |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 10 January 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- MSC — full drug profile →
Conditions studied
- ITP - Immune Thrombocytopenia — all drugs for ITP - Immune Thrombocytopenia →
Sponsor
Guangzhou Bio-gene Technology Co., Ltd — full company profile →
Who can join
Adults 4 to 75, any sex, with ITP - Immune Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a clinical study initiated by single-arm, single-center, multiple administration researchers. The main purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells in refractory ITP subjects. The subjects voluntarily signed the informed consent form, and after the evaluation of the screening period and the baseline period, they received 5 times of mesenchymal stem cell infusion in the treatment period, with a dose of 1 × 108/kg mesenchymal stem cells per time, with a frequency of 1 week between the first infusion and the second infusion (a time window of ±1 day), and the 3rd, 4th and 5th infusion were all 2 weeks apart from the last infusion (a time window of ±3 days). After all treatments were completed, the safety and effectiveness of D14, M1, M2, M3, M6, M9 and M12 were evaluated during the follow-up period. The subjects were followed up to M12 or those who met the withdrawal criteria withdrew early, whichever occurred first.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Innovative strategies for immune thrombocytopenia treatment: immunomodulatory mechanisms and clinical potential of mesenchymal stem cells.
Zhou X, Shan N. · · 2026 · PMID 41947170 · DOI 10.1186/s13287-026-05000-w
Verify or expand the search:
- PubMed search for NCT06813157
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MSC
Trials testing the same drug.
- NCT06823063 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD · Phase 1 · not yet recruiting
- NCT06788470 — Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulm · Phase 1, PHASE2 · recruiting
- NCT05697718 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke · Phase 1 · completed
- NCT04611256 — Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 · Phase 1 · unknown
- NCT03552848 — Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection · NA · unknown
Other recruiting trials for ITP - Immune Thrombocytopenia
Currently open trials in the same condition.
- NCT07093606 — Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura · NA · recruiting
- NCT07133659 — Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot S · Phase 4 · recruiting
- NCT06352281 — Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) · Phase 1, PHASE2 · recruiting
Other Guangzhou Bio-gene Technology Co., Ltd trials
Trials by the same sponsor.
- NCT07195617 — Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Mult · NA · not yet recruiting
- NCT07196124 — BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma · EARLY_PHASE1 · not yet recruiting
- NCT07196111 — BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors · EARLY_PHASE1 · not yet recruiting
- NCT07152210 — Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced C · NA · recruiting
- NCT07123662 — γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06813157 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Bio-gene Technology Co., Ltd
- Last refreshed: 6 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06813157.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing